LABORATORIO FARMAC.ERFO (RK7) — Cash Flow Reinvestment Rate

Latest as of December 2023: 1.38x

LABORATORIO FARMAC.ERFO (RK7) has a Cash Flow Reinvestment Rate of 1.38x as of December 2023, reinvesting €1.79 Million (capex €1.45 Million plus investments €345.57K) from operating cash flow of €1.30 Million. Explore RK7 capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

1.38x
(Capex + Investments) / Operating CF

Total Reinvested

€1.79 Million
Capex + Investments

Operating Cash Flow

€1.30 Million
EUR

Capital Expenditures

€1.45 Million
EUR

LABORATORIO FARMAC.ERFO Cash Flow Reinvestment Rate (2021–2023)

Historical reinvestment intensity for LABORATORIO FARMAC.ERFO across 3 annual periods. Also explore RK7 total assets for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for LABORATORIO FARMAC.ERFO (2021–2023)

Year-by-year capital reinvestment analysis for LABORATORIO FARMAC.ERFO. For live market cap and broader valuation context, see RK7 stock market capitalisation.

Year Reinvestment Rate Total Reinvested (EUR) Operating CF Capex YoY Change
2023 1.38x €1.79 Million €1.30 Million €1.45 Million ▼ -44.4%
2022 2.49x €1.89 Million €761.80K €1.18 Million ▲ +806.2%
2021 0.27x €623.55K €2.27 Million €242.84K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow